ArticleScience translational medicine2022
Tumor-intrinsic NLRP3-HSP70-TLR4 axis drives premetastatic niche development and hyperprogression during anti-PD-1 immunotherapy.
Open access · greenAbstract read
In one paragraph
Article in Science translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
4.0field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 50 citations in OpenAlex.
- Hepatocyte BDNF Acts as a Novel Immune Checkpoint to Restrain TLR4-Mediated Acute Hepatitis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Targeting arginine metabolism reverses bone immunosuppressive microenvironment and metastasis in ARID1A-deficient triple negative breast cancer.Nature communications · 2026Article
- Analysis of the NLRP3 inflammasome components expression in triple-negative breast cancer patients with and without BRCA1 mutations.Scientific reports · 2026Article
- Recent insights into HSP70: proteostasis and beyond.Frontiers in molecular biosciences · 2026Review
- Article
- KIRA6 restrains the generation of myeloid-derived suppressor cells and overcomes resistance to anti-PD-1 therapy.Cell death & disease · 2025Article
- IL33-induced lipid droplet formation in mature low-density neutrophils drives colorectal cancer liver metastasis.Cellular & molecular immunology · 2025Article
- Targeting SPHK1 in macrophages remodels the tumor microenvironment and enhances anti-PD-1 immunotherapy efficacy in colorectal cancer liver metastasis.Cancer communications (London, England) · 2025Article
- [Research Progress on the Potential Mechanisms of Hyper-progressive Disease in Immune Checkpoint Blockade Therapy of Solid Tumors].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2025Review
- Bridging the Gap in Breast Cancer Dormancy: Models, Mechanisms, and Translational Challenges.Pharmaceuticals (Basel, Switzerland) · 2025Review
- DownregulatedCells · 2025Article
- GLI2 Facilitates Tumor Immune Evasion and Immunotherapeutic Resistance by Coordinating WNT and Prostaglandin Signaling.Cancer research · 2025Article
- Targeting immune checkpoints in hepatocellular carcinoma therapy: toward combination strategies with curative potential.Experimental hematology & oncology · 2025Review
- Emerging role of bile acids in colorectal liver metastasis: From molecular mechanism to clinical significance (Review).International journal of oncology · 2025Review
- Narrative review of 3D bioprinting for the construction ofTranslational cancer research · 2025Review
- Predominance of hyperprogression in mucosal melanoma during anti-PD-1 monotherapy treatment.The oncologist · 2025Article
- Role of toll-like receptors in pulmonary immunity: mechanisms and therapeutic implications.Frontiers in immunology · 2025Review
- A novel classification method for LUAD that guides personalized immunotherapy on the basis of the cross-talk of coagulation- and macrophage-related genes.Frontiers in immunology · 2025Article
- Breaking the premetastatic niche barrier: the role of endothelial cells and therapeutic strategies.Theranostics · 2025Review
- The dual-function of HSP70 in immune response and tumor immunity: from molecular regulation to therapeutic innovations.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 1 country.
Balamayooran TheivanthiranDepartment of Medicine, Division of Medical Oncology, Duke Cancer Institute, Duke University, Durham, NC 27710, USA.ORCID 0000-0003-4816-199X
Nagendra YarlaDepartment of Medicine, Division of Medical Oncology, Duke Cancer Institute, Duke University, Durham, NC 27710, USA.
Tarek HaykalDepartment of Medicine, Division of Medical Oncology, Duke Cancer Institute, Duke University, Durham, NC 27710, USA.ORCID 0000-0002-8637-7292
Y-Van NguyenDepartment of Medicine, Division of Medical Oncology, Duke Cancer Institute, Duke University, Durham, NC 27710, USA.ORCID 0000-0003-1888-2147
Linda CaoDepartment of Medicine, Division of Medical Oncology, Duke Cancer Institute, Duke University, Durham, NC 27710, USA.ORCID 0000-0002-5916-1314
Michelle FerreiraDepartment of Medicine, Division of Medical Oncology, Duke Cancer Institute, Duke University, Durham, NC 27710, USA.ORCID 0000-0001-5335-349X
Alisha HoltzhausenLineberger Comprehensive Cancer Center, University of North Caroline at Chapel Hill, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.ORCID 0000-0003-3604-7401
Rami Al-RohilDepartment of Pathology, Duke Cancer Institute, Duke University Durham, Durham, NC 27710, USA.ORCID 0000-0002-9431-0530
April K S SalamaDepartment of Medicine, Division of Medical Oncology, Duke Cancer Institute, Duke University, Durham, NC 27710, USA.
Georgia M BeasleyDepartment of Surgery, Duke Cancer Institute, Duke University, Durham, NC 27710, USA.ORCID 0000-0001-6387-9030
Michael P PlebanekDepartment of Medicine, Division of Medical Oncology, Duke Cancer Institute, Duke University, Durham, NC 27710, USA.
Nicholas C DeVitoDepartment of Medicine, Division of Medical Oncology, Duke Cancer Institute, Duke University, Durham, NC 27710, USA.ORCID 0000-0001-7537-8647
Brent A HanksDepartment of Medicine, Division of Medical Oncology, Duke Cancer Institute, Duke University, Durham, NC 27710, USA.ORCID 0000-0002-2803-3272
Duke Medical Center · USDuke University · USUniversity of North Carolina at Chapel Hill · US
Funding
Investigating the PD-L1:NLRP3 signaling axis as a tumor intrinsic mechanism of adaptive resistance to anti-PD-1 antibody immunotherapyR37CA249085 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI HANKS, BRENT ALLEN · 2020 to 2025
$2.5MTumor-derived Exosome Induction of Dendritic Cell TolerizationF32CA247067 · NCI · DUKE UNIVERSITY · PI PLEBANEK, MICHAEL PAUL · 2020 to 2023
$209kNCI NIH HHS F32 CA247067NCI NIH HHS R37 CA249085
Abstract
The tumor-intrinsic NOD-, LRR- and pyrin domain-containing protein-3 (NLRP3) inflammasome-heat shock protein 70 (HSP70) signaling axis is triggered by CD8
Indexed as
MelanomaToll-Like Receptor 4Disease ProgressionHSP70 Heat-Shock ProteinsHumansImmunotherapyNLR Family, Pyrin Domain-Containing 3 ProteinTumor MicroenvironmentHSP70 Heat-Shock ProteinsNLR Family, Pyrin Domain-Containing 3 ProteinTLR4 protein, humanToll-Like Receptor 4
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.